CD8A and hepatocellular carcinoma: In an analysis of peripheral blood of a group of 10 patients undergoing liver SBRT (50–60 Gy/3–5 fractions) [16] for both primary and metastatic liver tumors (four patients liver metastases, one patient intrahepatic cholangiocarcinoma, five patients hepatocellular carcinoma), CD3+ T cell counts decreased in all but one patient after SBRT, while CD8+ T cell counts remained unchanged.